Press Releases

vTv Therapeutics and JDRF enter into a $6 million industry partnership to explore the effect of liver-selective glucokinase activator TTP399 as an insulin-adjunctive therapy in type 1 diabetes HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 6, 2017-- vTv Therapeutics Inc.

HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation

HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 2, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the second quarter ended June 30, 2017 . “With positive progress in our lead Alzheimer’s and diabetes programs, vTv is

HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 13, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), will be presented at the 2017

Lower doses of TTP273 may demonstrate a more pronounced reduction in HbA1c and other key endpoints HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 11, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small

HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced

-- Azeliragon is the only RAGE receptor antagonist in clinical development for Alzheimer’s Disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 1, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced the completion of enrollment for vTv’s Phase 3 placebo-controlled trial, STEADFAST

HIGH POINT, N.C. --(BUSINESS WIRE)--May 3, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today provided

HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 10, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today

Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer’s Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273 and TTP399 HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage

Oral small molecule GLP-1 receptor agonist met primary endpoint Company’s second successful Phase 2 diabetes trial in 2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 14, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced positive data from its Phase 2 study evaluating TTP273, an oral

HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 16, 2016-- vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that

HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 10, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will be participating in

HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 2, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and

HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 24, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the company’s Chief

HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 3, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company committed to the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, announced today that company Chief Medical

HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 8, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will

Phase 2b Trial Showed Positive Results In Slowing Cognitive Decline HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 7, 2016-- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to

HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 2, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that company Chief Medical Officer

TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Company Releases Q2 Earnings Results and Details Upcoming Program Milestones HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 16, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq:VTVT), a clinical-stage biopharmaceutical company

Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated treatment regimen HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 10, 2016-- Please replace the release with the following corrected version due to multiple revisions.

Analysis shows azeliragon 5mg/day resulted in steadily increasing delay in time to cognitive deterioration in mild Alzheimer’s disease patients Azeliragon designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation TORONTO --(BUSINESS WIRE)--Jul.

Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation – three of the principal causes of neuronal damage in AD HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 14, 2016-- vTv Therapeutics Inc.

HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will

Data show TTP399 improves glycemic control and insulin resistance without hypoglycemia NEW ORLEANS --(BUSINESS WIRE)--Jun. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for